Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA grew its position in Annexon, Inc. (NASDAQ:ANNX) by 9.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,160,886 shares of the company’s stock after acquiring an additional 96,085 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Annexon were worth $6,872,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. ProShare Advisors LLC purchased a new position in Annexon in the first quarter valued at about $87,000. Vanguard Group Inc. raised its holdings in shares of Annexon by 96.4% during the 1st quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock valued at $26,871,000 after buying an additional 1,839,329 shares during the period. American International Group Inc. lifted its position in Annexon by 46.3% during the 1st quarter. American International Group Inc. now owns 33,197 shares of the company’s stock worth $238,000 after acquiring an additional 10,510 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Annexon by 10,482.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,323,704 shares of the company’s stock worth $9,492,000 after acquiring an additional 1,311,195 shares during the period. Finally, Bayesian Capital Management LP acquired a new stake in Annexon in the first quarter valued at approximately $119,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ANNX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Annexon in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.80.

Insider Buying and Selling at Annexon

In other news, EVP Ted Yednock sold 4,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $7.10, for a total value of $31,950.00. Following the transaction, the executive vice president now directly owns 71,365 shares in the company, valued at approximately $506,691.50. This trade represents a 5.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 20,908 shares of company stock worth $135,768 over the last quarter. 12.67% of the stock is owned by corporate insiders.

Annexon Stock Performance

Shares of ANNX stock opened at $5.29 on Wednesday. The stock has a market capitalization of $563.86 million, a price-to-earnings ratio of -5.04 and a beta of 1.23. Annexon, Inc. has a one year low of $2.27 and a one year high of $8.40. The company’s 50-day simple moving average is $6.75 and its 200-day simple moving average is $5.95.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.